NATURAL PRODUCT RESEARCH AND DEVELOPMENT ›› 2023, Vol. 35 ›› Issue (3): 444-452.doi: 10.16333/j.1001-6880.2023.3.010

Previous Articles     Next Articles

Identification of phenylethanoid glycosides from Clerodendrum bungei and its mechanism of anti-human lung adenocarcinoma A549 cell in vitro

WANG Fen1,TANG Hao2,ZHOU Hou-yuan1,YU Xiang-rong1,ZHU Ke-jian2,LI Shun-xiang1,YU Na1 *,TANG Lin3*    

  1. 1School of Pharmacy,Hunan University of Chinese Medicine,Changsha 410208,China;2Hunan Academy of Chinese Medicine,Changsha 410006,China;3The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine,Changsha 410007,China
  • Online:2023-03-28 Published:2023-03-28

Abstract:

Clerodendrum bungei extract has a good anti-tumor effect.In order to identify the ingredients of the C. bungei extract and explore its impact on the A549 in vitro,the ultra-high-efficiency liquid chromatography-mass spectrometry technology,CCK-8,cell scratch,Transwell,Western blot,immunofluorescence and flow cytometry methods were used to detect. The 34 phenylethanoid glycosides compounds of the C. bungei extract were identified,of which the content of acteoside was 32.95%,and isoacteoside was 5.49%.The C. bungei extract can inhibit the proliferation,migration and invasion of A549 cellsin vitro,and the IC50 is 0.125 mg/mL.In addition,the C. bungei extract can reduce the expression of EphA2,P-AKT,mTOR,P-mTOR,P-GSK-3β,and β-cateninin in A549 cells,increase the expression of EphrinA1,reducing the expression of EphA2 in A549 cell membrane and membrane quality,and blocke the A549 cell cycle to the G1/S stage.This study has confirmed that the C. bungei is rich in phenylethanoid glycosides,especially acteoside and isoacteoside,and can achieve anti-lung cancer effect by regulating the EphA2/AKT/ mTOR pathway.

Key words: Clerodendrum bungei, phenylethanoid glycosides, A549, EphA2/AKT/mTOR pathway

CLC Number: